Mylan Current Ratio 2006-2018 | MYL

Current and historical current ratio for Mylan (MYL) from 2006 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Mylan current ratio for the three months ending December 31, 2018 was 1.39.
Mylan Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-12-31 $6.37B $4.59B 1.39
2018-09-30 $6.54B $5.18B 1.26
2018-06-30 $6.30B $4.86B 1.30
2018-03-31 $6.76B $6.39B 1.06
2017-12-31 $7.21B $6.39B 1.13
2017-09-30 $7.27B $4.98B 1.46
2017-06-30 $6.97B $5.17B 1.35
2017-03-31 $7.07B $4.52B 1.56
2016-12-31 $7.52B $5.04B 1.49
2016-09-30 $7.97B $9.55B 0.83
2016-06-30 $12.19B $3.78B 3.23
2016-03-31 $6.63B $3.96B 1.67
2015-12-31 $6.47B $4.12B 1.57
2015-09-30 $6.49B $3.68B 1.76
2015-06-30 $7.89B $5.37B 1.47
2015-03-31 $7.43B $5.29B 1.40
2014-12-31 $6.44B $5.30B 1.21
2014-09-30 $5.82B $4.47B 1.30
2014-06-30 $4.48B $2.60B 1.72
2014-03-31 $4.34B $2.65B 1.64
2013-12-31 $4.47B $2.96B 1.51
2013-09-30 $4.34B $2.56B 1.70
2013-06-30 $4.21B $2.33B 1.81
2013-03-31 $3.95B $2.28B 1.73
2012-12-31 $3.90B $2.19B 1.78
2012-09-30 $3.75B $2.17B 1.73
2012-06-30 $3.75B $2.16B 1.73
2012-03-31 $3.74B $2.11B 1.77
2011-12-31 $3.57B $2.56B 1.39
2011-09-30 $3.61B $2.38B 1.52
2011-06-30 $3.76B $2.52B 1.49
2011-03-31 $3.76B $2.39B 1.57
2010-12-31 $3.56B $1.81B 1.97
2010-09-30 $3.46B $1.72B 2.01
2010-06-30 $3.63B $1.63B 2.23
2010-03-31 $3.36B $1.64B 2.05
2009-12-31 $3.29B $1.72B 1.91
2009-09-30 $3.26B $1.58B 2.06
2009-06-30 $3.02B $1.42B 2.13
2009-03-31 $2.91B $1.34B 2.17
2008-12-31 $3.18B $1.55B 2.06
2008-09-30 $3.42B $1.82B 1.88
2008-06-30 $3.48B $2.11B 1.65
2008-03-31 $3.49B $2.22B 1.57
2007-12-31 $3.06B $2.00B 1.53
2007-09-30 $2.62B $0.77B 3.42
2007-06-30 $2.62B $0.83B 3.16
2007-03-31 $2.41B $0.70B 3.44
2006-12-31 $1.28B $0.29B 4.46
2006-09-30 $1.33B $0.26B 5.13
2006-06-30 $1.29B $0.29B 4.41
2006-03-31 $1.19B $0.27B 4.49
2005-12-31 $1.17B $0.26B 4.45
2005-09-30 $1.27B $0.27B 4.70
2005-06-30 $1.57B $0.26B 5.93
2005-03-31 $1.53B $0.25B 6.23
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $14.539B $11.434B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $50.172B 9.03
Teva Pharmaceutical Industries (TEVA) Israel $16.921B 5.84
Bausch Health Cos (BHC) Canada $8.584B 6.10
Dr Reddy's Laboratories (RDY) India $6.489B 25.88
Supernus Pharmaceuticals (SUPN) United States $2.008B 18.63
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.896B 3.08
Homology Medicines (FIXX) United States $1.048B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.953B 88.57
CymaBay Therapeutics (CBAY) United States $0.794B 0.00
Voyager Therapeutics (VYGR) United States $0.616B 0.00
Assembly Biosciences (ASMB) United States $0.502B 0.00
Akorn (AKRX) United States $0.432B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.389B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.215B 0.00
Sol-Gel Technologies (SLGL) Israel $0.132B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.102B 0.00
Acasti Pharma (ACST) Canada $0.083B 0.00
Teligent (TLGT) United States $0.070B 0.00
Agile Therapeutics (AGRX) United States $0.069B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.064B 0.00
Evoke Pharma (EVOK) United States $0.025B 0.00
Aevi Genomic Medicine (GNMX) United States $0.015B 0.00
China Pharma Holdings (CPHI) China $0.014B 0.00